Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1988 Feb;81(2):549–560. doi: 10.1172/JCI113353

Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome.

W A Gahl 1, I Bernardini 1, M Dalakas 1, W B Rizzo 1, G S Harper 1, J M Hoeg 1, O Hurko 1, J Bernar 1
PMCID: PMC329603  PMID: 3276734

Abstract

11 children with either cystinosis or Lowe's syndrome had a reduced content of plasma and muscle carnitine due to renal Fanconi syndrome. After treatment with oral L-carnitine, 100 mg/kg per d divided every 6 h, plasma carnitine concentrations became normal in all subjects within 2 d. Initial plasma free fatty acid concentrations, inversely related to free carnitine concentrations, were reduced after 7-20 mo of carnitine therapy. Muscle lipid accumulation, which varied directly with duration of carnitine deficiency (r = 0.73), improved significantly in three of seven rebiopsied patients after carnitine therapy. One Lowe's syndrome patient achieved a normal muscle carnitine level after therapy. Muscle carnitine levels remained low in all cystinosis patients, even though cystinotic muscle cells in culture took up L-[3H]carnitine normally. The half-life of plasma carnitine for cystinotic children given a single oral dose approximated 6.3 h; 14% of ingested L-carnitine was excreted within 24 h. Studies in a uremic patient with cystinosis showed that her plasma carnitine was in equilibrium with some larger compartment and may have been maintained by release of carnitine from the muscle during dialysis. Because oral L-carnitine corrects plasma carnitine deficiency, lowers plasma free fatty acid concentrations, and reverses muscle lipid accumulation in some patients, its use as therapy in renal Fanconi syndrome should be considered. However, its efficacy in restoring muscle carnitine to normal, and the optimal dosage regimen, have yet to be determined.

Full text

PDF
549

Images in this article

555Image
on p.555
556Image
on p.556
557Image
on p.557

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bach A. C., Schirardin H., Sihr M. O., Storck D. Free and total carnitine in human serum after oral ingestion of L-carnitine. Diabete Metab. 1983 May-Jun;9(2):121–124. [PubMed] [Google Scholar]
  2. Bellinghieri G., Savica V., Mallamace A., Di Stefano C., Consolo F., Spagnoli L. G., Villaschi S., Palmieri G., Corsi M., Maccari F. Correlation between increased serum and tissue L-carnitine levels and improved muscle symptoms in hemodialyzed patients. Am J Clin Nutr. 1983 Oct;38(4):523–531. doi: 10.1093/ajcn/38.4.523. [DOI] [PubMed] [Google Scholar]
  3. Bernardini I., Rizzo W. B., Dalakas M., Bernar J., Gahl W. A. Plasma and muscle free carnitine deficiency due to renal Fanconi syndrome. J Clin Invest. 1985 Apr;75(4):1124–1130. doi: 10.1172/JCI111806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bougneres P. F., Lacour B., di Giulio S., Assan R. Hypolipaemic effect of carnitine in uraemic patients. Lancet. 1979 Jun 30;1(8131):1401–1402. doi: 10.1016/s0140-6736(79)92032-4. [DOI] [PubMed] [Google Scholar]
  5. Broquist H. P. Carnitine biosynthesis and function. Introductory remarks. Fed Proc. 1982 Oct;41(12):2840–2842. [PubMed] [Google Scholar]
  6. Cederblad G. Effect of diet on plasma carnitine levels and urinary carnitine excretion in humans. Am J Clin Nutr. 1987 Apr;45(4):725–729. doi: 10.1093/ajcn/45.4.725. [DOI] [PubMed] [Google Scholar]
  7. Cederblad G., Lindstedt S., Lundholm K. Concentration of carnitine in human muscle tissue. Clin Chim Acta. 1974 Jun 28;53(3):311–321. doi: 10.1016/0009-8981(74)90270-8. [DOI] [PubMed] [Google Scholar]
  8. Di Donato S., Pelucchetti D., Rimoldi M., Mora M., Garavaglia B., Finocchiaro G. Systemic carnitine deficiency: clinical, biochemical, and morphological cure with L-carnitine. Neurology. 1984 Feb;34(2):157–162. doi: 10.1212/wnl.34.2.157. [DOI] [PubMed] [Google Scholar]
  9. Duran M., de Klerk J. B., Wadman S. K., Scholte H. R., Beekman R. P., Jennekens F. G. Systemic carnitine deficiency: benefit of oral carnitine supplements vs. persisting biochemical abnormalities. Eur J Pediatr. 1984 Aug;142(3):224–228. doi: 10.1007/BF00442456. [DOI] [PubMed] [Google Scholar]
  10. Engel A. G., Rebouche C. J. Carnitine metabolism and inborn errors. J Inherit Metab Dis. 1984;7 (Suppl 1):38–43. doi: 10.1007/BF03047372. [DOI] [PubMed] [Google Scholar]
  11. Engel A. G., Rebouche C. J., Wilson D. M., Glasgow A. M., Romshe C. A., Cruse R. P. Primary systemic carnitine deficiency. II. Renal handling of carnitine. Neurology. 1981 Jul;31(7):819–825. doi: 10.1212/wnl.31.7.819. [DOI] [PubMed] [Google Scholar]
  12. Engel W. K. Selective and nonselective susceptibility of muscle fiber types. A new approach to human neuromuscular diseases. Arch Neurol. 1970 Feb;22(2):97–117. doi: 10.1001/archneur.1970.00480200003001. [DOI] [PubMed] [Google Scholar]
  13. Frohlich J., Seccombe D. W., Hahn P., Dodek P., Hynie I. Effect of fasting on free and esterified carnitine levels in human serum and urine: correlation with serum levels of free fatty acids and beta-hydroxybutyrate. Metabolism. 1978 May;27(5):555–561. doi: 10.1016/0026-0495(78)90022-7. [DOI] [PubMed] [Google Scholar]
  14. Gahl W. A., Bashan N., Tietze F., Bernardini I., Schulman J. D. Cystine transport is defective in isolated leukocyte lysosomes from patients with cystinosis. Science. 1982 Sep 24;217(4566):1263–1265. doi: 10.1126/science.7112129. [DOI] [PubMed] [Google Scholar]
  15. Gahl W. A. Cystinosis coming of age. Adv Pediatr. 1986;33:95–126. [PubMed] [Google Scholar]
  16. Gahl W. A., Reed G. F., Thoene J. G., Schulman J. D., Rizzo W. B., Jonas A. J., Denman D. W., Schlesselman J. J., Corden B. J., Schneider J. A. Cysteamine therapy for children with nephropathic cystinosis. N Engl J Med. 1987 Apr 16;316(16):971–977. doi: 10.1056/NEJM198704163161602. [DOI] [PubMed] [Google Scholar]
  17. Gahl W. A., Tietze F., Bashan N., Bernardini I., Raiford D., Schulman J. D. Characteristics of cystine counter-transport in normal and cystinotic lysosome-rich leucocyte granular fractions. Biochem J. 1983 Nov 15;216(2):393–400. doi: 10.1042/bj2160393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Gretz N., Manz F., Augustin R., Barrat T. M., Bender-Götze C., Brandis M., Bremer H. J., Brodehl J., Broyer M., Bulla M. Survival time in cystinosis. A collaborative study. Proc Eur Dial Transplant Assoc. 1983;19:582–589. [PubMed] [Google Scholar]
  19. Gross C. J., Henderson L. M. Absorption of D- and L-carnitine by the intestine and kidney tubule in the rat. Biochim Biophys Acta. 1984 May 16;772(2):209–219. doi: 10.1016/0005-2736(84)90046-4. [DOI] [PubMed] [Google Scholar]
  20. Guarnieri G. F., Ranieri F., Toigo G., Vasile A., Ciman M., Rizzoli V., Moracchiello M., Campanacci L. Lipid-lowering effect of carnitine in chronically uremic patients treated with maintenance hemodialysis. Am J Clin Nutr. 1980 Jul;33(7):1489–1492. doi: 10.1093/ajcn/33.7.1489. [DOI] [PubMed] [Google Scholar]
  21. Gudjonsson H., Li B. U., Shug A. L., Olsen W. A. In vivo studies of intestinal carnitine absorption in rats. Gastroenterology. 1985 Jun;88(6):1880–1887. doi: 10.1016/0016-5085(85)90014-9. [DOI] [PubMed] [Google Scholar]
  22. Hamilton J. W., Li B. U., Shug A. L., Olsen W. A. Carnitine transport in human intestinal biopsy specimens. Demonstration of an active transport system. Gastroenterology. 1986 Jul;91(1):10–16. doi: 10.1016/0016-5085(86)90432-4. [DOI] [PubMed] [Google Scholar]
  23. Hoeg J. M., Schaefer E. J., Romano C. A., Bou E., Pikus A. M., Zech L. A., Bailey K. R., Gregg R. E., Wilson P. W., Sprecher D. L. Neomycin and plasma lipoproteins in type II hyperlipoproteinemia. Clin Pharmacol Ther. 1984 Oct;36(4):555–565. doi: 10.1038/clpt.1984.219. [DOI] [PubMed] [Google Scholar]
  24. Jonas A. J., Schneider J. A. Plasma cysteamine concentrations in children treated for cystinosis. J Pediatr. 1982 Feb;100(2):321–323. doi: 10.1016/s0022-3476(82)80665-3. [DOI] [PubMed] [Google Scholar]
  25. Karpati G., Carpenter S., Engel A. G., Watters G., Allen J., Rothman S., Klassen G., Mamer O. A. The syndrome of systemic carnitine deficiency. Clinical, morphologic, biochemical, and pathophysiologic features. Neurology. 1975 Jan;25(1):16–24. doi: 10.1212/wnl.25.1.16. [DOI] [PubMed] [Google Scholar]
  26. Kjernes U., Mølstad P. The effect of sulfhydryl blocking agents on the uptake of L-carnitine in an established human cell line (CCL 27). Scand J Clin Lab Invest. 1981 Apr;41(2):209–213. doi: 10.3109/00365518109092036. [DOI] [PubMed] [Google Scholar]
  27. Lacour B., Di Giulio S., Chanard J., Ciancioni C., Haguet M., Lebkiri B., Basile C., Drüeke T., Assan R., Funck-Brentano J. L. Carnitine improves lipid anomalies in haemodialysis patients. Lancet. 1980 Oct 11;2(8198):763–764. doi: 10.1016/s0140-6736(80)90384-0. [DOI] [PubMed] [Google Scholar]
  28. Matsuishi T., Hirata K., Terasawa K., Kato H., Yoshino M., Ohtaki E., Hirose F., Nonaka I., Sugiyama N., Ohta K. Successful carnitine treatment in two siblings having lipid storage myopathy with hypertrophic cardiomyopathy. Neuropediatrics. 1985 Feb;16(1):6–12. doi: 10.1055/s-2008-1052536. [DOI] [PubMed] [Google Scholar]
  29. McGarry J. D., Foster D. W. An improved and simplified radioisotopic assay for the determination of free and esterified carnitine. J Lipid Res. 1976 May;17(3):277–281. [PubMed] [Google Scholar]
  30. Moorthy A. V., Rosenblum M., Rajaram R., Shug A. L. A comparison of plasma and muscle carnitine levels in patients on peritoneal or hemodialysis for chronic renal failure. Am J Nephrol. 1983 Jul-Aug;3(4):205–208. doi: 10.1159/000166711. [DOI] [PubMed] [Google Scholar]
  31. Panzetta G., Bonadonna G., Giovene P., De Grandis D. Carnitine kinetics during dialysis. Evidence of unilateral transport from tissues to plasma. Nephron. 1985;41(3):230–234. doi: 10.1159/000183588. [DOI] [PubMed] [Google Scholar]
  32. Prockop L. D., Engel W. K., Shug A. L. Nearly fatal muscle carnitine deficiency with full recovery after replacement therapy. Neurology. 1983 Dec;33(12):1629–1631. doi: 10.1212/wnl.33.12.1629. [DOI] [PubMed] [Google Scholar]
  33. Rebouche C. J., Engel A. G. Carnitine metabolism and deficiency syndromes. Mayo Clin Proc. 1983 Aug;58(8):533–540. [PubMed] [Google Scholar]
  34. Rebouche C. J., Engel A. G. Carnitine transport in cultured muscle cells and skin fibroblasts from patients with primary systemic carnitine deficiency. In Vitro. 1982 May;18(5):495–500. doi: 10.1007/BF02796479. [DOI] [PubMed] [Google Scholar]
  35. Rebouche C. J., Engel A. G. Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes. Evidence for alterations in tissue carnitine transport. J Clin Invest. 1984 Mar;73(3):857–867. doi: 10.1172/JCI111281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Rebouche C. J., Mack D. L., Edmonson P. F. L-Carnitine dissimilation in the gastrointestinal tract of the rat. Biochemistry. 1984 Dec 18;23(26):6422–6426. doi: 10.1021/bi00321a022. [DOI] [PubMed] [Google Scholar]
  37. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., Klenk D. C. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985 Oct;150(1):76–85. doi: 10.1016/0003-2697(85)90442-7. [DOI] [PubMed] [Google Scholar]
  38. Steinmann B., Bachmann C., Colombo J. P., Gitzelmann R. The renal handling of carnitine in patients with selective tubulopathy and with Fanconi syndrome. Pediatr Res. 1987 Feb;21(2):201–204. doi: 10.1203/00006450-198702000-00018. [DOI] [PubMed] [Google Scholar]
  39. Steinmann B., Bachmann C., Colombo J. P., Gitzelmann R. The renal handling of carnitine in patients with selective tubulopathy and with Fanconi syndrome. Pediatr Res. 1987 Feb;21(2):201–204. doi: 10.1203/00006450-198702000-00018. [DOI] [PubMed] [Google Scholar]
  40. Thoene J. G., Oshima R. G., Crawhall J. C., Olson D. L., Schneider J. A. Cystinosis. Intracellular cystine depletion by aminothiols in vitro and in vivo. J Clin Invest. 1976 Jul;58(1):180–189. doi: 10.1172/JCI108448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Tsai A. C., Romsos D. R., Leveille G. A. Significance of dietary carnitine for growth and carnitine turnover in rats. J Nutr. 1974 Jun;104(6):782–792. doi: 10.1093/jn/104.6.782. [DOI] [PubMed] [Google Scholar]
  42. Tserng K. Y., Kliegman R. M., Miettinen E. L., Kalhan S. C. A rapid, simple, and sensitive procedure for the determination of free fatty acids in plasma using glass capillary column gas-liquid chromatography. J Lipid Res. 1981 Jul;22(5):852–858. [PubMed] [Google Scholar]
  43. Warnick G. R., Benderson J., Albers J. J. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982 Jun;28(6):1379–1388. [PubMed] [Google Scholar]
  44. Weschler A., Aviram M., Levin M., Better O. S., Brook J. G. High dose of L-carnitine increases platelet aggregation and plasma triglyceride levels in uremic patients on hemodialysis. Nephron. 1984;38(2):120–124. doi: 10.1159/000183292. [DOI] [PubMed] [Google Scholar]
  45. Wilson S. H., Schrier B. K., Farber J. L., Thompson E. J., Rosenberg R. N., Blume A. J., Nirenberg M. W. Markers for gene expression in cultured cells from the nervous system. J Biol Chem. 1972 May 25;247(10):3159–3169. [PubMed] [Google Scholar]
  46. Yasin R., Van Beers G., Nurse K. C., Al-Ani S., Landon D. N., Thompson E. J. A quantitative technique for growing human adult skeletal muscle in culture starting from mononucleated cells. J Neurol Sci. 1977 Jul;32(3):347–360. doi: 10.1016/0022-510x(77)90018-1. [DOI] [PubMed] [Google Scholar]
  47. von Petrykowski W., Ketelsen U. P., Schmidt-Sommerfield E., Penn D., Sawicka E., Struck E., Lehnert W., Haap K., Strassburg H. M. Primary systemic carnitine deficiency under successful therapy: clinical, biochemical, ultrahistochemical and renal clearance studies. Clin Neuropathol. 1985 Mar-Apr;4(2):63–71. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES